Saturday - June 13, 2026
GSK's Momelotinib Granted Orphan Drug Designations in the U.S. and EU for VEXAS Syndrome
June 13, 2026
LONDON, England, June 13 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on June 12, 2026:

* * *

GSK's momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome

* VEXAS syndrome is a rare, life-threatening haemato-inflammatory condition with no approved treatments

* ATLAS phase II/III trial in VEXAS underway, advancing momelotinib's broader development programme< . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products